99 Wall Street, Suite 232, New York, NY 10005

Need Help? Call : (800) 991-3756

Class Action Cases

A class action has been filed on behalf of RETA Investors. Click "Join this Class Action" above.

Attorneys

Reata Pharmaceuticals, Inc.

Join Class Action »

Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) from October 15, 2019 through August 7, 2020 (the “Class Period”). The lawsuit seeks to recover damages for Reata Pharmaceuticals, Inc. investors under the federal securities laws.

If you bought Reata Pharmaceuticals, Inc. securities between October 15, 2019 through August 7, 2020, and would like to join the action, please click “Join This Class Action,” above.

Press Release

SHAREHOLDER ALERT: Zhang Investor Law Announces a Securities Class Action Lawsuit Against Reata Pharmaceuticals, Inc. – RETA

New York, N.Y., November 12, 2020. Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between October 15, 2019 and August 7, 2020, inclusive (the “Class Period”).

To join the RETA class action, go to http://zhanginvestorlaw.com/cases/reata-pharmaceuticals-inc/ call Sophie Zhang, Esq. toll-free at 800-991-3756 or email info@zhanginvestorlaw.com for information on the class action.

Lead plaintiff status is not required to seek compensation. You may retain counsel of your choice. You may remain an absent class member and take no action at this time.

According to the lawsuit,  throughout the Class Period  (1) the MOXIe Part 2 study results were insufficient to support a single study marketing approval of omaveloxolone for the treatment of Friedreich’s ataxia (“FA”) in the U.S. without additional evidence; (2) as a result, it was foreseeably likely that the FDA would not accept marketing approval of omaveloxolone for the treatment of FA in the U.S. based on the MOXIe Part 2 study results; and (3) as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 14, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://zhanginvestorlaw.com/cases/reata-pharmaceuticals-inc/ or to discuss your rights or interests regarding this class action, please contact Sophie Zhang, Esq. of Zhang Investor Law toll free at 800-991-3756 or via e-mail at info@zhanginvestorlaw.com.

Zhang Investor Law represents investors worldwide.